Astellas, Pfizer look to broaden Xtandi's patient base with new prostate cancer win after 8 years – FiercePharma

  1. Astellas, Pfizer look to expand Xtandi’s patient base after 8 years with new prostate cancer win.FiercePharma
  2. Enzalutamide/Leuprolide prolongs MFS in nmHSPC with high-risk biochemical recurrenceTargeted oncology
  3. Pfizer, Astellas’ Xtandi meets primary endpoint in Phase 3 trial in prostate cancer subtypeSeeking Alpha
  4. Enzalutamide plus leuprolide improves MFS in nonmetastatic castration-sensitive prostate cancer.OncLive
  5. Enzalutamide plus ADT improves time to PSA progression in mHSPCTargeted oncology
  6. See full coverage on Google News



Leave a Reply

Your email address will not be published. Required fields are marked *